Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Deferred Revenue: 2016-2023

Historic Current Deferred Revenue for Spyre Therapeutics (SYRE) over the last 3 years, with Jun 2023 value amounting to $930,000.

  • Spyre Therapeutics' Current Deferred Revenue rose 219.59% to $930,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $930,000, marking a year-over-year increase of 219.59%. This contributed to the annual value of $2.7 million for FY2022, which is 14.29% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Current Deferred Revenue of $930,000 as of Q2 2023, which was up 207.95% from $302,000 recorded in Q1 2023.
  • Spyre Therapeutics' 5-year Current Deferred Revenue high stood at $19.2 million for Q1 2021, and its period low was $291,000 during Q2 2022.
  • For the 3-year period, Spyre Therapeutics' Current Deferred Revenue averaged around $3.9 million, with its median value being $2.2 million (2021).
  • In the last 5 years, Spyre Therapeutics' Current Deferred Revenue tumbled by 94.74% in 2022 and then spiked by 219.59% in 2023.
  • Spyre Therapeutics' Current Deferred Revenue (Quarterly) stood at $2.4 million in 2021, then rose by 14.29% to $2.7 million in 2022, then surged by 219.59% to $930,000 in 2023.
  • Its last three reported values are $930,000 in Q2 2023, $302,000 for Q1 2023, and $2.7 million during Q4 2022.